Samuel A Wells
Affiliation: National Institutes of Health
- Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an updateSamuel A Wells
Cancer Genetics Branch, National Cancer Institute, National Institutes of Health, Building 37, Room 10106A, 37 Convent Drive, Bethesda, Maryland 20814, USA
J Clin Endocrinol Metab 98:3149-64. 2013..In this manuscript, we summarize how recent discoveries have enhanced our understanding of the molecular basis of these diseases and led to improvements in the diagnosis and management of affected patients...
- Targeting the RET pathway in thyroid cancerSamuel A Wells
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Clin Cancer Res 15:7119-23. 2009..Also, recently developed molecular therapeutics that target the RET pathway have shown activity in clinical trials of patients with advanced MTC, a disease for which there has been no effective therapy...
- Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trialSamuel A Wells
Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Building 10, Room 13N 240E MSC 1206, 9000 Rockville Pike, Bethesda, MD 20892, USA
J Clin Oncol 30:134-41. 2012....
- Update: the status of clinical trials with kinase inhibitors in thyroid cancerSamuel A Wells
Cancer Genetics Branch S A W, National Cancer Institute, Bethesda, Maryland 20892 and Dipartimento di Medicina Molecolare e Biotecnologie Mediche M S, Universita di Napoli Federico II, 80131 Napoli, Italy
J Clin Endocrinol Metab 99:1543-55. 2014....
- Activation of the mTOR pathway in primary medullary thyroid carcinoma and lymph node metastasesAnna Tamburrino
Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 18:3532-40. 2012..Understanding the molecular pathogenesis of medullary thyroid carcinoma (MTC) is prerequisite to the design of targeted therapies for patients with advanced disease...
- The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutationsChan Kwon Jung
Department of Pathology C K J, Y E N, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 Department of Hospital Pathology C K J, The Catholic University of Korea, Seoul 137 701, Republic of Korea and Radiation Epidemiology and Biostatistics Branches J H L, A v B, M P L, A J S, Division of Cancer Epidemiology and Genetics and Cancer Genetics Branch S A W, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
J Clin Endocrinol Metab 99:E276-85. 2014..Thyroid cancer incidence rates in the United States and globally have increased steadily over the last 40 years, primarily due to a tripling of the incidence of papillary thyroid carcinoma (PTC)...